Clinical Trial

A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation

Study acronym: MANGROVE
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This is a randomized study to compare the efficacy and safety of zanubrutinib plus rituximab versus bendamustine plus rituximab in previously untreated participants with mantle cell lymphoma (MCL) who are not eligible for stem cell transplantation.
Protocol Amendment History 32 amendments
This ClinicalTrials.gov record has been amended 32 times since 2019-06-27; most recent amendment 2026-05-15.
Status change: Recruiting → Active, Not Recruiting 2024-01-09
Trial Details
NCT Number NCT04002297
Lead Sponsor BeOne Medicines
Conditions Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
Enrollment 510 participants
Start Date 2019-08-20
Primary Completion 2027-03 (estimated)
Study Completion 2031-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-18